http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103193722-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 |
| filingDate | 2012-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103193722-B |
| titleOfInvention | Novel quinazoline quinoline nitrogen mustards compound and preparation method thereof and cancer therapeutic applications |
| abstract | A kind of novel quinazoline quinoline nitrogen mustards compound, is characterized in that: one end has mustargen alkanisation group; The other end has the quinazoline structure that 6,7-replaces, substituent Rn 1 being positioned on quinazoline parent 4, is the mustargen group of 2-, 3-, 4-; Substituent Rn 2 , Rn 3 laying respectively at 6 of quinazoline parent, on 7, is methoxyethoxy, methoxyl group, morpholine propoxy-, 3-tetrahydrofuran oxygen base and hydroxyl.Structure is such as formula A.Experiment shows, this compounds can cause being cross-linked of DNA, is a kind of bifunctional alkylating agents.Anti-tumor in vivo activity experiment shows, this compounds has good activity.Moreover, this compounds also has the unexistent advantage of chlormethine series pharmaceuticals, and namely toxicity is less.Meanwhile, this compounds is easy to synthesis, and overall yield is higher.All advantages, show this compounds and have the great potential becoming anti-tumor medicine. |
| priorityDate | 2012-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.